Xifaxan
Product Images NDC 69189-0309

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 69189-0309). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rifaximin 200 mg Tablet (6918903091)

Packaging label for XIFAXAN 200 mg tablet containing the active ingredient rifaximin. The label indicates manufacturing by Salix Pharm, includes lot numbers, and an expiration date of 05/06/2016. The NDC number 69189-0309 and the labeler Avera McKennan Hospital, Sioux Falls, SD, are also shown.*

FDA Label Image

Figure 3 (Figure3)

A diagram titled 'Trial 3 Study Design' showing the timeline and phases of a clinical study. It includes screening/treatment phases, maintenance phases, and multiple treatment phases with specified durations and follow-up periods. The diagram highlights primary evaluation and efficacy analysis points and indicates patient pathways including non-responders and end-of-study follow-up. A horizontal arrow notes daily/weekly symptom diary collection throughout.*

FDA Label Image

Chemical Structure (Image 01)

Chemical structure diagram of the active ingredient in XIFAXAN, showing a complex organic molecule with multiple rings, hydroxyl groups, and methyl substitutions.*

FDA Label Image

Figure 1 (Image 02)

A Kaplan-Meier curve showing the proportion of patients without breakthrough hepatic encephalopathy (HE) on the Y-axis over days post-randomization on the X-axis, comparing XIFAXAN versus placebo. The graph includes hazard ratio and confidence interval data, illustrating higher patient retention without breakthrough HE for XIFAXAN.*

FDA Label Image

Figure 2 (Image 03)

A Kaplan-Meier survival curve graph showing the proportion of patients without HE-related hospitalization over days post-randomization. Two groups are plotted: XIFAXAN and Placebo, with XIFAXAN showing a higher proportion over time. The graph includes a hazard ratio (0.500) with 95% confidence interval and a log-rank p-value (0.0129).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.